Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.51 |
| ▸ | INSR | P06213 | 10/20 | 0.51 |
| ▸ | MET | P08581 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
| ▸ | ETV6 | P41212 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24073793 | 1.00 | ALK (0.51) | ALKINSRMETFGFR1BRD4 | |
| SCHEMBL30266494 | 1.00 | ALK (0.51) | ALKINSRMETFGFR1BRD4 | |
| SCHEMBL30462524 | 0.89 | INSR (0.49) | ALKINSRMETFGFR1EGFR | |
| SCHEMBL24073795 | 0.89 | INSR (0.49) | ALKINSRMETFGFR1EGFR | |
| SCHEMBL25835424 | 0.89 | INSR (0.49) | ALKINSRMETFGFR1EGFR | |
| SCHEMBL24073796 | 0.88 | FGFR1 (0.54) | ALKINSRMETFGFR1 | |
| SCHEMBL24073437 | 0.88 | FGFR1 (0.54) | ALKINSRMETFGFR1 | |
| SCHEMBL30266417 | 0.84 | INSR (0.49) | ALKINSRMETBRD4EGFR | |
| SCHEMBL24073791 | 0.84 | INSR (0.49) | ALKINSRMETBRD4EGFR | |
| SCHEMBL25835411 | 0.84 | INSR (0.49) | ALKINSRMETBRD4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | ALK 87/4885INSR 1450/4885MET 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.